RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE is indicated for the treatment of Duodenal Ulcer; Pathological Hypersecretory Conditions; Zollinger-Ellison Syndrome; Systemic Mastocytosis; Gastric Ulcer; Gastroesophageal Reflux Disease; Erosive Esophagitis.
Development Insights
Details
- Status
- Discontinued
- First Approved
- 1997-07-31
- Routes
- ORAL, INJECTION
- Dosage Forms
- SYRUP, TABLET, CAPSULE, INJECTABLE
Companies
RANITIDINE HYDROCHLORIDE Approval History
What RANITIDINE HYDROCHLORIDE Treats
7 indicationsRANITIDINE HYDROCHLORIDE is approved for 7 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Duodenal Ulcer
- Pathological Hypersecretory Conditions
- Zollinger-Ellison Syndrome
- Systemic Mastocytosis
- Gastric Ulcer
- Gastroesophageal Reflux Disease
- Erosive Esophagitis
RANITIDINE HYDROCHLORIDE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to RANITIDINE HYDROCHLORIDE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02195804 | 1144.3 | Ph 1 | completed | Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RANITIDINE HYDROCHLORIDE FDA Label Details
Indications & Usage
RANITIDINE HYDROCHLORIDE is indicated for the treatment of Duodenal Ulcer; Pathological Hypersecretory Conditions; Zollinger-Ellison Syndrome; Systemic Mastocytosis; Gastric Ulcer; Gastroesophageal Reflux Disease; Erosive Esophagitis.
Looking for the branded version?
ZANTAC 300
Full clinical data, patents, trials, and competitive landscape for ranitidine hydrochloride.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment